Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2012 (2012), Article ID 986725, 9 pages
http://dx.doi.org/10.1155/2012/986725
Review Article

Present and Future of EGFR Inhibitors for Head and Neck Squamous Cell Cancer

1Department of Otorhinolaryngology and Head and Neck Surgery, Ohtawara Red Cross Hospital, 2-7-3, Sumiyoshi-cho, Ohtawara City, Tochigi 324-8686, Japan
2National Institute of Sensory Organs, National Tokyo Medical Center, 2-5-1, Higashigaoka, Meguro, Tokyo 152-8902, Japan
3Department of Oral Function and Molecular Biology, Ohu University, 31-1, Mitsumido, Tomita-machi, Koriyama City, Fukushima 963-8611, Japan

Received 25 November 2011; Accepted 22 January 2012

Academic Editor: M. Roach

Copyright © 2012 Yuh Baba et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Cripps, E. Winquist, M. C. Devries, D. Stys-Norman, and R. Gilbert, “Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer,” Current Oncology, vol. 17, no. 3, pp. 37–48, 2010. View at Google Scholar
  2. F. R. Khuri, D. M. Shin, B. S. Glisson, S. M. Lippman, and W. K. Hong, “Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck: current status and future directions,” Seminars in Oncology, vol. 27, no. 4, pp. 25–33, 2000. View at Google Scholar
  3. A. Forastiere, W. Koch, A. Trotti, and D. Sidransky, “Head and neck cancer,” New England Journal of Medicine, vol. 345, no. 26, pp. 1890–1900, 2001. View at Google Scholar · View at Scopus
  4. V. M. van Houten, M. W. van den Brekel, F. Denkers et al., “Molecular diagnosis of head and neck cancer,” Recent Results in Cancer Research, vol. 157, pp. 90–106, 2000. View at Google Scholar · View at Scopus
  5. F. Ciardiello and G. Tortora, “Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs,” European Journal of Cancer, vol. 39, no. 10, pp. 1348–1354, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. D. Saranath, R. G. Panchal, R. Nair, A. R. Mehta, V. D. Sanghavi, and M. G. Deo, “Amplification and overexpression of epidermal growth factor receptor gene in human oropharyngeal cancer,” European Journal of Cancer B, vol. 28, no. 2, pp. 139–143, 1992. View at Publisher · View at Google Scholar · View at Scopus
  7. B. Burtness, “The role of cetuximab in the treatment of squamous cell cancer of the head and neck,” Expert Opinion on Biological Therapy, vol. 5, no. 8, pp. 1085–1093, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. C. A. Carter, R. J. Kelly, and G. Giaccone, “Small-molecule inhibitors of the human epidermal receptor family,” Expert Opinion on Investigational Drugs, vol. 18, no. 12, pp. 1829–1842, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Sordella, D. W. Bell, D. A. Haber, and J. Settleman, “Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways,” Science, vol. 305, no. 5687, pp. 1163–1167, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Loeffler-Ragg, M. Witsch-Baumgartner, A. Tzankov et al., “Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma,” European Journal of Cancer, vol. 42, no. 1, pp. 109–111, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. T. Taguchi, M. Tsukuda, Y. Imagawa-Ishiguro, Y. Kato, and D. Sano, “Involvement of EGFR in the response of squamous cell carcinoma of the head and neck cell lines to gefitinib,” Oncology Reports, vol. 19, no. 1, pp. 65–71, 2008. View at Google Scholar · View at Scopus
  12. S. Ozawa, Y. Kato, S. Ito et al., “Restoration of BRAK/CXCl14 gene expression by gefitinib is associated with antitumor efficacy of the drug in head and neck squamous cell carcinoma,” Cancer Science, vol. 100, no. 11, pp. 2202–2209, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. K. K. Wong, “Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors,” Lung Cancer, vol. 60, no. 2, pp. S10–S18, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. Baba, M. Fujii, Y. Tokumaru, and Y. Kato, “New strategy in head and neck cancer: combination therapy targeting the PI3Kinase/Akt and EGFR signaling pathways,” Hypotheses in Clinical Medicine. In press. View at Publisher · View at Google Scholar
  15. E. E. W. Cohen, F. Rosen, W. M. Stadler et al., “Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck,” Journal of Clinical Oncology, vol. 21, no. 10, pp. 1980–1987, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. D. Soulieres, N. N. Senzer, E. E. Vokes, M. Hidalgo, S. S. Agarvala, and L. L. Siu, “Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck,” Journal of Clinical Oncology, vol. 22, no. 1, pp. 77–85, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. D. A. Eberhard, B. E. Johnson, L. C. Amler et al., “Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib,” Journal of Clinical Oncology, vol. 23, no. 25, pp. 5900–5909, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. J. A. Anderson, J. C. Irish, C. M. McLachlin, and B. Y. Ngan, “H-ras oncogene mutation and human papillomavirus infection in oral carcinomas,” Archives of Otolaryngology—Head and Neck Surgery, vol. 120, no. 7, pp. 755–760, 1994. View at Google Scholar · View at Scopus
  19. B. A. Frederick, B. A. Helfrich, C. D. Coldren et al., “Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma,” Molecular Cancer Therapeutics, vol. 6, no. 6, pp. 1683–1691, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. L. H. Kalish, R. A. Kwong, I. E. Cole, R. M. Gallagher, R. L. Sutherland, and E. A. Musgrove, “Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines,” Clinical Cancer Research, vol. 10, no. 22, pp. 7764–7774, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. P. Timpson, A. S. Wilson, G. M. Lehrbach, R. L. Sutherland, E. A. Musgrove, and R. J. Daly, “Aberrant expression of cortactin in head and neck squamous cell carcinoma cells is associated with enhanced cell proliferation and resistance to the epidermal growth factor receptor inhibitor gefitinib,” Cancer Research, vol. 67, no. 19, pp. 9304–9314, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Brognard, E. Sierecki, T. Gao, and A. C. Newton, “PHLPP and a Second Isoform, PHLPP2, Differentially Attenuate the Amplitude of Akt Signaling by Regulating Distinct Akt Isoforms,” Molecular Cell, vol. 25, no. 6, pp. 917–931, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Bellacosa, D. de Feo, A. K. Godwin et al., “Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas,” International Journal of Cancer, vol. 64, no. 4, pp. 280–285, 1995. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Q. Cheng, B. Ruggeri, W. M. Klein et al., “Amplification of AKT2 in human pancreatic cancer cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 8, pp. 3636–3641, 1996. View at Publisher · View at Google Scholar · View at Scopus
  25. J. D. Carpten, A. L. Faber, C. Horn et al., “A transforming mutation in the pleckstrin homology domain of AKT1 in cancer,” Nature, vol. 448, no. 7152, pp. 439–444, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. E. V. Haar, S. I. Lee, S. Bandhakavi, T. J. Griffin, and D. H. Kim, “Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40,” Nature Cell Biology, vol. 9, no. 3, pp. 316–323, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. S. V. Madhunapantula, A. Sharma, and G. P. Robertson, “PRAS40 deregulates apoptosis in malignant melanoma,” Cancer Research, vol. 67, no. 8, pp. 3626–3636, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Inoki, Y. Li, T. Xu, and K. L. Guan, “Rheb GTpase is a direct target of TSC2 GAP activity and regulates mTOR signaling,” Genes and Development, vol. 17, no. 15, pp. 1829–1834, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. K. Inoki, H. Ouyang, Y. Li, and K. L. Guan, “Signaling by target of rapamycin proteins in cell growth control,” Microbiology and Molecular Biology Reviews, vol. 69, no. 1, pp. 79–100, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. D. D. Sarbassov, D. A. Guertin, S. M. Ali, and D. M. Sabatini, “Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex,” Science, vol. 307, no. 5712, pp. 1098–1101, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. L. S. Harrington, G. M. Findlay, A. Gray et al., “The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins,” Journal of Cell Biology, vol. 166, no. 2, pp. 213–223, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. P. K. Vogt, M. Gymnopoulos, and J. R. Hart, “PI 3-kinase and cancer: changing accents,” Current Opinion in Genetics and Development, vol. 19, no. 1, pp. 12–17, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. A. K. Gupta, W. G. McKenna, C. N. Weber et al., “Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction,” Clinical Cancer Research, vol. 8, no. 3, pp. 885–892, 2002. View at Google Scholar · View at Scopus
  34. J. Tsurutani, J. Fukuoka, H. Tsurutani et al., “Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors,” Journal of Clinical Oncology, vol. 24, no. 2, pp. 306–314, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. E. Forgacs, E. J. Biesterveld, Y. Sekido et al., “Mutation analysis of the PTEN/MMAC1 gene in lung cancer,” Oncogene, vol. 17, no. 12, pp. 1557–1565, 1998. View at Google Scholar · View at Scopus
  36. J. Bertram, J. W. Peacock, L. Fazli et al., “Loss of PTEN is associated with progression to androgen independence,” Prostate, vol. 66, no. 9, pp. 895–902, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. L. Shayesteh, Y. Lu, W. L. Kuo et al., “PlK3CA is implicated as an oncogene in ovarian cancer,” Nature Genetics, vol. 21, no. 1, pp. 99–102, 1999. View at Publisher · View at Google Scholar · View at Scopus
  38. Y. Y. Ma, S. J. Wei, Y. C. Lin et al., “PIK3CA as an oncogene in cervical cancer,” Oncogene, vol. 19, no. 23, pp. 2739–2744, 2000. View at Google Scholar · View at Scopus
  39. Y. Samuels and K. Ericson, “Oncogenic PI3K and its role in cancer,” Current Opinion in Oncology, vol. 18, no. 1, pp. 77–82, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. T. Nakashima and G. L. Clayman, “Antisense inhibition of cyclin D1 in human head and neck squamous cell carcinoma,” Archives of Otolaryngology—Head and Neck Surgery, vol. 126, no. 8, pp. 957–961, 2000. View at Google Scholar · View at Scopus
  41. Y. Baba, M. Tsukuda, I. Mochimatsu et al., “Cytostatic effect of inostamycin, an inhibitor of cytidine 5′-diphosphate 1,2-diacyl-sn-glycerol (CDP-DG): inositol transferase, on oral squamous cell carcinoma cell lines,” Cell Biology International, vol. 25, no. 7, pp. 613–620, 2001. View at Publisher · View at Google Scholar · View at Scopus
  42. Y. Baba, M. Tsukuda, I. Mochimatsu et al., “Inostamycin, an inhibitor of cytidine 5′-diphosphate 1,2-diacyl-sn-glycerol (CDP-DG): inositol transferase, suppresses invasion ability by reducing productions of matrix metalloproteinase-2 and -9 and cell motility in HSC-4 tongue carcinoma cell line,” Clinical and Experimental Metastasis, vol. 18, no. 3, pp. 273–279, 2000. View at Publisher · View at Google Scholar · View at Scopus
  43. J. M. Cherrington, L. M. Strawn, and L. K. Shawver, “New paradigms for the treatment of cancer: the role of anti-angiogenesis agents,” Advances in Cancer Research, vol. 79, pp. 2–38, 2000. View at Google Scholar · View at Scopus
  44. T. Takahashi, H. Ueno, and M. Shibuya, “VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells,” Oncogene, vol. 18, no. 13, pp. 2221–2230, 1999. View at Google Scholar · View at Scopus
  45. S. Rousseau, F. Houle, J. Landry, and J. Huot, “P38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells,” Oncogene, vol. 15, no. 18, pp. 2169–2177, 1997. View at Google Scholar · View at Scopus
  46. K. J. Gotink and H. M. W. Verheul, “Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?” Angiogenesis, vol. 13, no. 1, pp. 1–14, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. Q. T. Ho and C. J. Kuo, “Vascular endothelial growth factor: biology and therapeutic applications,” International Journal of Biochemistry and Cell Biology, vol. 39, no. 7-8, pp. 1349–1357, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. Y. Baba, Y. Kato, I. Mochimatsu et al., “Inostamycin suppresses vascular endothelial growth factor-stimulated growth and migration of human umbilical vein endothelial cells,” Clinical & Experimental Metastasis, vol. 21, no. 5, pp. 419–425, 2004. View at Google Scholar · View at Scopus
  49. J. Kaur, M. Sawhney, S. DattaGupta, N. K. Shukla, A. Srivastava, and R. Ralhan, “Clinical significance of Phosphatidyl Inositol Synthase overexpression in oral cancer,” BMC Cancer, vol. 10, article no. 168, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. Y. Baba, Y. Kato, and K. Ogawa, “Inostamycin prevents malignant phenotype of cancer: inhibition of phosphatidylinositol synthesis provides a therapeutic advantage for head and neck squamous cell carcinoma,” Cell Biology International, vol. 34, no. 2, pp. 171–175, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. H. E. Jones, C. M. Dutkowski, D. Barrow, M. E. Harper, A. E. Wakeling, and R. I. Nicholson, “New EGF-R selective tyrosine kinase inhibitor reveals variable growth responses in prostate carcinoma cell lines PC-3 and DU-145,” International Journal of Cancer, vol. 71, no. 6, pp. 1010–1018, 1997. View at Publisher · View at Google Scholar · View at Scopus
  52. J. M. Knowlden, I. R. Hutcheson, D. Barrow, J. M. W. Gee, and R. I. Nicholson, “Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor,” Endocrinology, vol. 146, no. 11, pp. 4609–4618, 2005. View at Publisher · View at Google Scholar · View at Scopus
  53. Y. J. Choi, J. K. Rho, B. S. Jeon et al., “Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors,” Cancer Chemotherapy and Pharmacology, vol. 66, no. 2, pp. 381–388, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. H. E. Jones, L. Goddard, J. M. W. Gee et al., “Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iresa) in human breast and prostate cancer cells,” Endocrine-Related Cancer, vol. 11, no. 4, pp. 793–814, 2004. View at Publisher · View at Google Scholar · View at Scopus
  55. H. E. Jones, J. M. W. Gee, D. Barrow, D. Tonge, B. Holloway, and R. I. Nicholson, “Inhibition of insulin receptor isoform-A signalling restores sensitivity to gefitinib in previously de novo resistant colon cancer cells,” British Journal of Cancer, vol. 95, no. 2, pp. 172–180, 2006. View at Publisher · View at Google Scholar · View at Scopus
  56. C. J. Barnes, K. Ohshiro, S. K. Rayala, A. K. El-Naggar, and R. Kumar, “Insulin-like growth factor receptor as a therapeutic target in head and neck cancer,” Clinical Cancer Research, vol. 13, no. 14, pp. 4291–4299, 2007. View at Publisher · View at Google Scholar · View at Scopus
  57. M. G. Slomiany, L. A. Black, M. M. Kibbey, M. A. Tingler, T. A. Day, and S. A. Rosenzweig, “Insulin-like growth factor-1 receptor and ligand targeting in head and neck squamous cell carcinoma,” Cancer Letters, vol. 248, no. 2, pp. 269–279, 2007. View at Publisher · View at Google Scholar · View at Scopus
  58. M. Rebucci, P. Peixoto, A. Dewitte et al., “Mechanisms underlying resistance to cetuximab in the HNSCC cell line: role of AKT inhibition in bypassing this resistance,” International Journal of Oncology, vol. 38, no. 1, pp. 189–200, 2011. View at Publisher · View at Google Scholar · View at Scopus
  59. V. Sriuranpong, J. I. Park, P. Amornphimoltham, V. Patel, B. D. Nelkin, and J. S. Gutkind, “Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system,” Cancer Research, vol. 63, no. 11, pp. 2948–2956, 2003. View at Google Scholar · View at Scopus
  60. C. H. Squarize, R. M. Castilho, V. Sriuranpong, D. S. Pinto, and J. S. Gutkind, “Molecular cross-talk between the NFκB and STAT3 signaling pathways in head and neck squamous cell carcinoma,” Neoplasia, vol. 8, no. 9, pp. 733–746, 2006. View at Publisher · View at Google Scholar · View at Scopus
  61. N. T. Ihle, G. Paine-Murrieta, M. I. Berggren et al., “The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts,” Molecular Cancer Therapeutics, vol. 4, no. 9, pp. 1349–1357, 2005. View at Publisher · View at Google Scholar · View at Scopus
  62. M. G. Mohi, C. Boulton, T. L. Gu et al., “Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 9, pp. 3130–3135, 2004. View at Publisher · View at Google Scholar · View at Scopus
  63. D. C. Birle and D. W. Hedley, “Signaling interactions of rapamycin combined with erlotinib in cervical carcinoma xenografts,” Molecular Cancer Therapeutics, vol. 5, no. 10, pp. 2494–2502, 2006. View at Publisher · View at Google Scholar · View at Scopus
  64. E. Buck, A. Eyzaguirre, E. Brown et al., “Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors,” Molecular Cancer Therapeutics, vol. 5, no. 11, pp. 2676–2684, 2006. View at Publisher · View at Google Scholar · View at Scopus
  65. L. J. Costa, R. M. Gemmill, and H. A. Drabkin, “Upstream Signaling Inhibition Enhances Rapamycin Effect on Growth of Kidney Cancer Cells,” Urology, vol. 69, no. 3, pp. 596–602, 2007. View at Publisher · View at Google Scholar · View at Scopus
  66. A. B. Hjelmeland, K. P. Lattimore, B. E. Fee et al., “The combination of novel low molecular weight inhibitors of RAF (LBT613) and target of rapamycin (RAD001) decreases glioma proliferation and invasion,” Molecular Cancer Therapeutics, vol. 6, no. 9, pp. 2449–2457, 2007. View at Publisher · View at Google Scholar · View at Scopus
  67. A. Jimeno, P. Kulesza, J. Wheelhouse et al., “Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy,” British Journal of Cancer, vol. 96, no. 6, pp. 952–959, 2007. View at Publisher · View at Google Scholar · View at Scopus
  68. D. Li, T. Shimamura, H. Ji et al., “Bronchial and Peripheral Murine Lung Carcinomas Induced by T790M-L858R Mutant EGFR Respond to HKI-272 and Rapamycin Combination Therapy,” Cancer Cell, vol. 12, no. 1, pp. 81–93, 2007. View at Publisher · View at Google Scholar · View at Scopus
  69. Q. W. Fan, C. K. Cheng, T. P. Nicolaides et al., “A dual phosphoinositide-3-kinase α/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma,” Cancer Research, vol. 67, no. 17, pp. 7960–7965, 2007. View at Publisher · View at Google Scholar · View at Scopus